Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Unraveling the role of exercise in cancer suppression

2.

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer

5.

Survivors of childhood brain cancer are more likely to be held back in school


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot